NSE
Astec LifeSciences LimitedASTEC
Astec LifeSciences Limited is an Indian pharmaceutical company involved in the manufacturing of APIs (Active Pharmaceutical Ingredients) and formulations.
| Key products | APIs, Formulations |
|---|---|
| Geography | India |
| Competitors | Dr Reddy's Laboratories, Cipla |
AI-generated overview — verify before relying on it.
Net institutional flow
+₹0.4 Cr
Institutional buyers
3 in / 3 out
High-impact filings
0 · tilt Neutral
Next corporate action
—
| # | Company | Inst. flow ₹Cr | Deals | Hi-impact | Filing mom. | Buzz | News |
|---|---|---|---|---|---|---|---|
| 1 | ATALREAL | +₹7.2 Cr | 157 | — | — | — | — |
| 2 | QUADFUTURE | +₹0.1 Cr | 148 | — | — | — | — |
| 3 | MOBIKWIK | +₹0.1 Cr | 83 | — | — | — | — |
| 4 | ASTECThis | +₹0 Cr | 8 | — | — | — | — |
| 5 | MTNL | +₹0 Cr | 2 | — | — | — | — |
| 6 | GATECH | +₹0 Cr | 8 | — | — | — | — |
| 7 | IRMENERGY | −₹2.2 Cr | 328 | — | — | — | — |
Ranked by net institutional flow (buys − sells, ₹Cr). Filing momentum = bullish − bearish filings; Buzz = news+social sentiment. Curate peers in the company admin.
SWOT
Strengths
- • Diversified portfolio with a strong presence in API manufacturing
- • Established relationships with major pharmaceutical companies
- • State-of-the-art manufacturing facilities
- • Strong research and development capabilities
Weaknesses
- • Dependence on a few key customers
- • High operating costs due to regulatory compliance
- • Competition from low-cost producers in emerging markets
- • Limited presence in the US market
Opportunities
- • Growing demand for generic APIs in emerging markets
- • Increasing focus on sustainable and eco-friendly manufacturing practices
- • Expansion into new product categories such as biosimilars
- • Partnerships with pharmaceutical companies to develop new products
Threats
- • Intensifying competition from generic drug manufacturers
- • Regulatory changes and compliance risks
- • Fluctuations in raw material prices and supply chain disruptions
- • Economic downturn affecting consumer spending on healthcare
AI-generated from our data — verify before relying on it.
- 2026-05-18BulkBUY · ₹9.3 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-05-18BulkSELL · ₹9.3 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-05-18NetDay net −₹0 Cr
- 2026-04-10BulkSELL · ₹7.1 CrMANSI SHARE AND STOCK BROKING PRIVATE LIMITED
- 2026-04-10BulkBUY · ₹8.6 CrMANSI SHARE AND STOCK BROKING PRIVATE LIMITED
- 2026-04-10BulkBUY · ₹11.9 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-04-10BulkSELL · ₹11.9 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-04-10NetDay net +₹1.5 Cr
- 2026-03-25BulkSELL · ₹13.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-03-25BulkBUY · ₹13.2 CrNK SECURITIES RESEARCH PRIVATE LIMITED
- 2026-03-25NetDay net +₹0 Cr
Merged from deals, filings, corporate actions and news — newest first. Compact rolls each day up to net flow + counts. Scope with the range above.
Filings that matter
No scored filings for ASTEC yet.
8 deals · 2026-03-25 → 2026-05-18
| Date | Counterparty | Type | Side | Value |
|---|---|---|---|---|
| 2026-05-18 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹9.3 Cr |
| 2026-05-18 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹9.3 Cr |
| 2026-04-10 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | Prop / churn | SELL | ₹7.1 Cr |
| 2026-04-10 | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | Prop / churn | BUY | ₹8.6 Cr |
| 2026-04-10 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹11.9 Cr |
| 2026-04-10 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹11.9 Cr |
| 2026-03-25 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | SELL | ₹13.2 Cr |
| 2026-03-25 | NK SECURITIES RESEARCH PRIVATE LIMITED | Prop / churn | BUY | ₹13.2 Cr |
8 deals in the selected window — corporate actions are scoped to the same period. ~2 years of history available.
News & chatter on ASTEC
RSS News
0No recent news.
Google News RSS — links open the source.
Investdesk
0No articles yet.
Our coverage.
No Reddit chatter.
r/ posts mentioning the company.
Twitter / X
0No posts.
Posts mentioning the company.